RESUMO
INTRODUCTION: Gastric cancer is third leading cause of cancer-related deaths worldwide and remarkably threatens human health and life. BAIAP2L2 is an epithelial-specific BAR domain protein that considered to be closely related to cell migration. In this study, we explored the specific role of BAIAP2L2 in human gastric cancer. METHODS: BAIAP2L2 expression was analyzed via online database and immunohistochemistry. The proliferation was detected using CCK8 and colony formation assay. The migration and invasion was confirmed by transwell assay, and the apoptosis of gastric cancer cells was detected by flow cytometry. RESULTS: BAIAP2L2 was highly expressed in tumour tissues and its expression significantly correlated with tumor diameter, T stage, pTNM stage and lymph node metastasis, respectively. Compared with GES-1 cells, SGC7901, MKN28, MKN45, AGS and BGC-823 tumor cells were all presented a high-expression of BAIAP2L2. The in vitro results showed that knockdown of BAIAP2L2 inhibited the proliferation, migration and invasion, and induced the apoptosis of gastric cancer cell. Further, knockdown of BAIAP2L2 inhibited the expression of the related proteins of AKT/mTOR and Wnt3a/ß-catenin signaling pathways. CONCLUSION: BAIAP2L2 is upregulated in gastric cancer, and knockdown of BAIAP2L2 inhibited the proliferation and metastasis through the inactivation of AKT/mTOR and Wnt3a/ß-catenin signaling pathways.
Assuntos
Proteínas Proto-Oncogênicas c-akt/metabolismo , Neoplasias Gástricas/enzimologia , Serina-Treonina Quinases TOR/metabolismo , Via de Sinalização Wnt , Proteína Wnt3A/metabolismo , Idoso , Apoptose , Linhagem Celular Tumoral , Movimento Celular , Proliferação de Células , Progressão da Doença , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Metástase Neoplásica , Neoplasias Gástricas/genética , Neoplasias Gástricas/patologia , Proteína Wnt3A/genéticaRESUMO
AIM: To compare the clinical effect of small incision-assisted laparoscopic splenectomy (LS) and open splenectomy in the treatment of hematologic disease. METHODS: The clinical data of 60 cases of small incision-assisted LS and 66 cases of splenectomy from October 1993 to May 2012 were retrospectively analyzed. RESULTS: The blood loss, enterokinesia time, off-bed activity times, hospitalization time, and incidence of complications in the laparoscopic group decreased significantly than the open group. There was no significance of difference between the 2 groups in the mean operating time and medical costs (P>0.05). CONCLUSIONS: Clinical effects of patients treated by small incision-assisted LS were better than those treated by open splenectomy. Small incision-assisted LS has advantages of microinvasion, safety, effectiveness, and quick recovery in the treatment of hematologic disease.